Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $2

Benzinga · 1d ago
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1.25 to $2.